 |
|
Photo copyright Martin Wall
|
What does it do? Borage oil is derived from the seeds of the
borage (Borago officinalis) plant. This large plant with blue, star-shaped flowers is
found throughout Europe and North Africa. It is naturalized to North America.1
Borage oil, evening primrose oil, and black
currant seed oil contain gamma linolenic acid (GLA), a fatty acid that the body converts to a
hormone-like substance called prostaglandin E1 (PGE1). PGE1 has anti-inflammatory properties
and may also act as a blood thinner and blood vessel dilator.
Linoleic acid, a common fatty acid found in nuts
and seeds and most vegetable oils (including borage oil), should theoretically convert to
PGE1. But many things can interfere with this conversion, including disease, the aging
process, saturated fat, hydrogenated oils,
blood sugar problems, and inadequate vitamin C, magnesium, zinc, and B vitamins. Supplements that provide GLA circumvent these
conversion problems, leading to more predictable formation of PGE1.2
Borage seed oil is the richest source of gamma linolenic acid (GLA) and contains
20–26% GLA. While GLA from evening primrose oil has been widely researched, scientific
evidence supporting the use of borage oil has been limited. Nonetheless, one preliminary
trial3 and two double-blind trials4 5 have shown that borage
oil, 1.1–2.8 grams per day for at least three months, reduces symptoms of rheumatoid
arthritis.
Borage oil has also been used to treat people with atopic dermatitis (eczema) in preliminary trials, with reductions in skin
inflammation, dryness, scaliness, and itch, without side effects being reported.6
However, a controlled study using 360 mg daily of GLA from borage oil, in patients with atopic
dermatitis (3–17 years of age) was unable to reproduce these results.7 In
another preliminary study, a group of children with infantile seborrheic dermatitis were treated with
borage oil (0.5 ml) applied to the diaper region twice daily.8 Within ten to twelve
days, all of the children were free from skin lesions, even in the areas not treated with
borage. Moreover, using the oil topically two to three times a week kept the seborrhea in
remission until the patients were six to seven months old. There were no relapses after the
oil was discontinued.
Where is it found? Borage oil is found primarily in
supplements. Its presumed active ingredient, GLA, can also be found in black currant seed oil
and evening primrose oil supplements. However,
it is not known whether the effects of these three oils in the body, are the same.
Borage oil has been used
in connection with the following conditions (refer to the individual
health concern for complete information):
Who is likely to be deficient? Many people in Western
societies may be at least partially GLA-deficient as a result of aging, glucose intolerance,
dietary fat intake, and other problems, though
the exact incidence of deficiency remains unknown. People with deficiencies benefit from
supplemental GLA intake from borage oil, black currant seed oil, or evening primrose oil.
Those with premenstrual syndrome,9 diabetes,10 scleroderma,11 Sjogren’s
syndrome,12 tardive
dyskinesia,13 eczema,14 and
other skin conditions15 may have a metabolic block that interferes with the
body’s ability to make GLA. However, most clinical trials supplementing GLA for these
conditions has used evening primrose oil, and not borage oil.
How much is usually taken? For the treatment of rheumatoid arthritis, the amounts of GLA from borage
used in successful double-blind trials were 1.4–2.8 grams daily for at least two
months.16 17 Although 360 mg of GLA daily from borage oil has been used
to treat people with eczema, controlled research has not
supported its use for this condition.18 Topically, 0.5 ml of borage oil may be
applied to areas of seborrhea daily for two
weeks, and then three times a week until the condition is stable.19
Are there any side effects or interactions?
Borageseeds contain small amounts of liver toxins called pyrrolizidine alkaloids
(PA). However, testing has not demonstrated the presence of the alkaloid in the seed
oil.20 Most commercially available borage seed oil is, therefore, likely to be
PA-free and presents no risk of PA toxicity. Minor side effects from borage oil use can
include bloating, nausea, indigestion, and
headache.21
At the time of writing, there were no well-known drug interactions
with borage oil.
References:
1. Wren RC. Potter’s New Cyclopedia of Botanical Drugs and
Preparations. Essex, England: C.W. Daniel and Co., 1988, 41.
2. Horrobin DF. The importance of gamma-linolenic acid and prostaglandin
E1 in human nutrition and medicine. J Holistic Med 1981;3:118–39.
3. Pullman-Mooar S, Laposata M, Lem D, et al. Alteration of the cellular
fatty acid profile and the production of eicosanoids in human monocytes by gamma-linolenic
acid. Arthritis Rheum 1990;33:1526–33.
4. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis
with gammalinolenic acid. Ann Intern Med 1993;119:867–73.
5. Zurier RB, Rossetti RG, Jacobson EW, et al. Gamma-linolenic acid
treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis
Rheum 1996;39:1808–17.
6. Landi G. Oral administration of borage oil in atopic dermatitis. J
Appl Cosmetology 1993;11:115–20.
7. Borreck S, Hildebrandt A, Forster J. Borage seed oil and atopic
dermatitis. Klinische Pediatrie 1997;203:100–4.
8. Tolleson A, Frithz A. Borage oil, an effective new treatment for
infantile seborrhoeic dermatitis. Br J Dermatol 1993;25:95.
9. Horrobin DF, Manku M, Brush M, et al. Abnormalities in plasma
essential fatty acid levels in women with pre-menstrual syndrome and with non-malignant breast
disease. J Nutr Med 1991;2:259–64.
10. Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy
with gamma-linolenic acid. Diabetes Care 1993;16:8–15.
11. Horrobin DF. Essential fatty acid metabolism in diseases of
connective tissue with special reference to scleroderma and to Sjogren’s syndrome.
Med Hypotheses 1984;14:233–47.
12. Horrobin DF, Campbell A. Sjogren’s syndrome and the sicca
syndrome: the role of prostaglandin E1 deficiency. Treatment with essential fatty acids and
vitamin C. Med Hypotheses 1980;6:225–32.
13. Vaddadi KS, Gilleard CJ. Essential fatty acids, tardive dyskinesia,
and schizophrenia. In Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical
Medicine. Horrobin DF (ed). New York: Alan R Liss, 1990, 333–43.
14. Manku MS, Horrobin, DF, Morse NL, et al. Essential fatty acids in the
plasma phospholipids of patients with atopic eczema. Br J Dermatol 1984;110:643.
15. Horrobin DF. Essential fatty acids in clinical dermatology. J Am
Acad Dermatol 1989;20:1045–53.
16. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis
with gammalinolenic acid. Ann Intern Med 1993;119:867–73.
17. Zurier RB, Rossetti RG, Jacobson EW, et al. Gamma-linolenic acid
treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis
Rheum 1996;39:1808–17.
18. Landi G. Oral administration of borage oil in atopic dermatitis.
J Appl Cosmetology 1993;11:115–20.
19. Tolleson A, Frithz A. Borage oil, an effective new treatment for
infantile seborrhoeic dermatitis. Br J Dermatol 1993;25:95.
20. Parvais O, Vander Stricht B, Vanhaelen-Fastré R,Vanhaelen M. TLC
detection of pyrrolizidine alkaloids in oil extracted from the seeds of Borago officinalis.
J Planar Chromatography 1994;7:80–2.
21. Awang DVC. Borage. Can Pharm J 1990;123:121–3.
Copyright © 2002 Healthnotes, Inc. All rights reserved.
www.healthnotes.com
Learn more about Healthnotes, the company.
Learn more about the authors of Healthnotes.
The information presented in Healthnotes is for informational
purposes only. It is based on scientific studies (human, animal, or in vitro),
clinical experience, or traditional usage as cited in each article. The results reported may
not necessarily occur in all individuals. For many of the conditions discussed, treatment with
prescription or over-the-counter medication is also available. Consult your doctor,
practitioner, and/or pharmacist for any health problem and before using any supplements or
before making any changes in prescribed medications. Information expires December 2003.
|